The FDA's decision to lift the shortage on branded tirzepatide will impact patients relying on compounded versions of the weight loss drug.
The Food and Drug Administration announced that branded tirzepatide, the active ingredient in Eli Lilly's weight loss drug Zepbound, is no longer in short supply. That decision will largely prevent compounding pharmacies from making and selling cheaper versions of the drug in the next two to three months.
It will also leave some patients in limbo, closing a niche market for compounded tirzepatide that patients say helped fill a gap in care for those who say they simply can't afford to pay out of pocket for Zepbound.Baillies, a human resources specialist based in Milwaukee, Wisconsin, has been attempting to lose weight and dealing with chronic autoimmune issues for years, so she turned to a cheaper alternative: a compounded, off-brand version of tirzepatide. Tirzepatide is the active ingredient in Zepbound and in Eli Lilly's diabetes counterpart Mounjaro, which are part of a class of highly popular medications called GLP-1 receptor agonists. She said compounded tirzepatide has helped change her life dramatically since she began taking it in June, alleviating pain from her autoimmune issues and helping her lose about 52 pounds. She said it costs her around $350 per month. But soon, compounded versions of tirzepatide could become inaccessible to Baillies and other patients who rely on them. Patients and health-care experts said that could force some consumers to stockpile doses, switch to other treatments, or stop receiving care altogether due to financial constraints. Others could turn to a potentially unsafe method of mixing vials themselves.— a decision that will largely prevent compounding pharmacies from making and selling cheaper versions of the drug in the next two to three months., pharmacists can legally make compounded versions of brand-name medications. But drugmakers and some health experts have pushed back against the practice because the FDA does not approve compounded drugs, which are essentially custom-made copies prescribed by a doctor to meet a specific patient's needs
Tirzepatide Compounding Pharmacies Drug Shortages Weight Loss Healthcare Costs
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Ends Tirzepatide Shortage Exception, Allowing Compounding Pharmacies 60-90 Day TransitionThe Food and Drug Administration (FDA) has declared that the active ingredient in Eli Lilly's weight loss drug Zepbound is no longer in shortage, effectively preventing compounding pharmacies from producing unbranded versions. However, the FDA will grant a 60 to 90-day transition period during which it will not penalize pharmacies for making compounded tirzepatide, giving patients time to switch to the branded drug. This decision marks the end of a period during which certain pharmacies could compound, distribute, or dispense tirzepatide without facing violations related to the treatment's shortage status.
Read more »
FDA Ends Shortage Status for Tirzepatide, Allowing Compounding Pharmacies to Make Unbranded VersionsThe Food and Drug Administration (FDA) announced that the active ingredient in weight loss drug Zepbound, tirzepatide, is no longer in shortage. This decision will eventually prevent compounding pharmacies from making unbranded versions of the injection. However, the FDA will provide a 60 to 90-day transition period during which it will not take action against pharmacies producing compounded tirzepatide, giving patients time to switch to the branded version.
Read more »
FDA Declares End to Tirzepatide Shortage, Impacting Weight Loss Drug and Diabetes TreatmentThe FDA has ended the shortage declaration for tirzepatide, the active ingredient in Eli Lilly's weight-loss drug Zepbound and diabetes treatment Mounjaro. This decision will eventually bar compounding pharmacies from making unbranded versions of the injection but will allow a 60 to 90-day transition period for patients to switch.
Read more »
FDA Stands By Tirzepatide Shortage Decision, Compounding Pharmacies Face DeadlineThe FDA is ending the tirzepatide shortage declaration, meaning compounding pharmacies must stop making the drug within 90 days. The decision comes after legal challenges and a reevaluation.
Read more »
FDA Ends Shortage Exception for Weight Loss Drug Ingredient, Giving Pharmacies Transition PeriodThe FDA has declared the active ingredient in Eli Lilly's weight loss drug Zepbound, tirzepatide, no longer in shortage, effectively ending compounding pharmacies' ability to make unbranded versions. However, a 60 to 90-day transition period will allow patients to switch to the branded drug.
Read more »
FDA Ends Shortage of Obesity Drugs, Phased Out GenericsThe FDA has declared the shortage of Eli Lilly's obesity and diabetes drugs, Zepbound and Mounjaro, resolved, requiring pharmacies to phase out generic versions. This impacts patient access and pricing.
Read more »